Biolegend, 502319, Ultra-LEAF™ Purified anti-human GM-CSF Antibody, 100μg

Granulocyte/macrophage - colony stimulating factor (GM-CSF) is a hematopoietic factor that is produced by activated T cells, B cells, mast cells, macrophages, fibroblasts, and endothelial cells. In addition to supporting colony formation of granulocyte/macrophage progenitors, GM-CSF is a growth factor for erythroid, megakaryocyte, and eosinophil progenitors.
100μg
Verified Reactivity: Human
Reported Reactivity: Cynomolgus, Rhesus
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli-expressed, recombinant human GM-CSF.
Formulation: 0.2 µm filtered in phosphate-buffered solution, pH 7.2, containing no preservative.
Endotoxin Level: Less than 0.01 EU/µg of the protein (< 0.001 ng/µg of the protein) as determined by the LAL test.
Preparation: The Ultra-LEAF™ (Low Endotoxin, Azide-Free) antibody was purified by affinity chromatography.
Concentration: The antibody is bottled at the concentration indicated on the vial, typically between 2 mg/mL and 3 mg/mL. Older lots may have also been bottled at 1 mg/mL. To obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C. This Ultra-LEAF™ solution contains no preservative; handle under aseptic conditions.
Application: Neut - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by neutralization of the proliferation induced by recombinant human GM-CSF (0.3 ng/mL) on TF-1 human erythroleukemia cells. ND50 range: 0.1 - 0.8 µg/mL. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: Additional reported applications (for the relevant formats) include: ELISA1-4 or ELISPOT3,4 Detection, Neutralization1, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated5,6 and acetone-fixed7 frozen tissue sections, and immunocytochemistry.Note: For testing human GM-CSF in serum or plasma, BioLegend's ELISA Max™ Sets (Cat. No. 432001 to 432006) are specially developed and recommended.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. (ELISA, Neut, IP) Abrams J, et al. 1994. Eosinophils in Allergy and Inflammation. Marcel Dekker New York. p.133. (ELISA) Bacchetta R, et al. 1990. J. Immunol. 144:902. (ELISA) Kita H, et al. 1991. J. Exp. Med. 174:745. (ELISA) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. (IHC) Andersson J, et al. 1994. Immunology 83:16. (IHC) Rasouli J, et al. 2015. J. Immunol. 11:5085-93. (IHC)
Product Citations: Xu P, et al. 2020. Cancer Immunol Res. 8:1193. PubMed
RRID: AB_2814393 (BioLegend Cat. No. 502319) AB_2814394 (BioLegend Cat. No. 502320)
Structure: Cytokine; 22 kD (Mammalian)
Bioactivity: Growth/development factor for granulocyte/macrophage progenitors; differentiates myeloblasts/monoblasts; synergizes with Epo proliferation of erythroid/megakaryocytic progenitors
Cell Sources: T cells, macrophages, fibroblasts, endothelial cells, mast cells
Cell Targets: Granulocyte/macrophage/erythroid/megakaryocytic progenitors, myeloblasts, monoblasts
Receptors: Heterodimer GM-CSFR α subunit (CDw116); β-subunit (CDw131), which is also shared with the IL-3 and IL-5 receptor α chains
Biology Area: Cell Biology, Stem Cells
Molecular Family: Cytokines/Chemokines, Growth Factors
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Demetri G, et al. 1991. Blood 78:2791. 3. Fan D, et al. 1991. In vivo 5:571. 4. Negrin R, et al. 1992. Adv. Pharmacol. 23:263.
Regulation: Synergistic with IL-1, IL-3, G-CSF; E21R competitive antagonist for receptor binding; stored in ECM with heparan sulfate proteoglycans
Gene ID: 1437
UniProt: View information about GM-CSF on UniProt.org
Clone: BVD2-21C11
Regulatory Status: RUO
Other Names: Granulocyte/macrophage colony-stimulating factor, CSF-α, Pluripoietin-α, Eosinophil colony stimulating factor (Eo-CSF), Burst promoting activity (BPA)
Isotype: Rat IgG2a, κ
Q: Do you guarantee that your antibodies are totally pathogen free?
A: BioLegend does not test for pathogens in-house aside from the GoInVivo™ product line. However, upon request, this can be tested on a custom basis with an outside, independent laboratory.
Q: Does BioLegend test each Ultra-LEAF™ antibody by functional assay?
A: No, BioLegend does not test Ultra-LEAF™ antibodies by functional assays unless otherwise indicated. Due to the possible complexities and variations of uses of biofunctional antibodies in different assays and because of the large product portfolio, BioLegend does not currently perform functional assays as a routine QC for the antibodies. However, we do provide references in which the antibodies were used for functional assays and we do perform QC to verify the specificity and quality of the antibody based on our strict specification criteria.
Q: Does BioLegend test each Ultra-LEAF™ antibody for potential pathogens?
A: No, BioLegend does not test for pathogens in-house unless otherwise indicated.  However, we can recommend an outside vendor to perform this testing as needed.
Q: Have you tested this Ultra-LEAF™ antibody for in vivo or in vitro applications?
A: We don't test our antibodies for in vivo or in vitro applications unless otherwise indicated. Depending on the product, the TDS may describe literature supporting usage of a particular product for bioassay. It may be best to further consult the literature to find clone specific information.